Pungent ginger components modulates human cytochrome P450 enzymes in vitro

Acta Pharmacologica Sinica

Volumn 34, Issue 9, 2013, Pages 1237-1242

  Li, Mian ^a   Chen, Pei Zhan ^a   Yue, Qing Xi ^a   Li, Jing Quan ^a,b   Chu, Rui Ai ^a,b   Zhang, Wei ^c   Wang, Hui ^a,b  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b BEIJING HOSPITAL   (China)

^c ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

CYP2C19; CYP2C9; CYP2D6; CYP3A4; Cytochrome P450 enzyme system; Dietary supplements; Drug diet interactions; Ginger rhizome; Gingerol

Indexed keywords

(10) GINGEROL; (6) GINGEROL; (8) GINGEROL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; MESSENGER RNA;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

CATECHOLS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ALCOHOLS; GINGER; HEP G2 CELLS; HUMANS;

EID: 84883686763     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.49     Document Type: Article

References (35)

1. Kawai T, Kinoshita K, Koyama K, Takahashi K. Anti-emetic principles of Magnolia obovata bark and Zingiber officinale rhizome. Planta Med 1994; 60: 17-20.
2. Chrubasik S, Pittler MH, Roufogalis BD. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine 2005; 12: 684-701.
3. Grant KL, Lutz RB. Alternative therapies: ginger. Am J Health Syst Pharm 2000; 57: 945-7.
4. Wei W, Chang YL, Xiao DW, Ping L, Lian WQ. Simultaneous determination of 6-gingerol, 8-gingerol, 10-gingerol and 6-shogaol in rat plasma by liquid chromatography-mass spectrometry: Application to pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 671-9.
5. Govindarajan VS. Ginger - chemistry, technology, and quality evaluation: part 1. Crit Rev Food Sci Nutr 1982; 17: 1-96.
6. Young HY, Luo YL, Cheng HY, Hsieh WC, Liao JC, Peng WH. Analgesic and anti-inflammatory activities of [6]-gingerol. J Ethnopharmacol 2005; 96: 207-10.
7. Kiuchi F, Iwakami S, Shibuya M, Hanaoka F, Sankawa U. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem Pharm Bull (Tokyo) 1992; 40: 387-91.
8. Shoji N, Iwasa A, Takemoto T, Ishida Y, Ohizumi Y. Cardiotonic principles of ginger (Zingiber officinale Roscoe). J Pharm Sci 1982; 71: 1174-5.
9. Ueki S, Miyoshi M, Shido O, Hasegawa J, Watanabe T. Systemic administration of [6]-gingerol, a pungent constituent of ginger, induces hypothermia in rats via an inhibitory effect on metabolic rate. Eur J Pharmacol 2008; 584: 87-92.
10. Park KK, Chun KS, Lee JM, Lee SS, Surh YJ. Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Lett 1998; 129: 139-44.
11. Park YJ, Wen J, Bang S, Park SW, Song SY. [6]-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells. Yonsei Med J 2006; 47: 688-97.
12. Ishiguro K, Ando T, Maeda O, Ohmiya N, Niwa Y, Kadomatsu K, et al. Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms. Biochem Biophys Res Commun 2007; 362: 218-23.
13. Lee SH, Cekanova M, Baek SJ. Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Mol Carcinog 2008; 47: 197-208.
14. Lee HS, Seo EY, Kang NE, Kim WK. [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J Nutr Biochem 2008; 19: 313-9.
15. Haniadka R, Rajeev AG, Palatty PL, Arora R, Baliga MS. Zingiber officinale (ginger) as an anti-emetic in cancer chemotherapy: a review. J Altern Complement Med 2012; 18: 440-4.
16. Schwertner HA, Rios DC. High-performance liquid chromatographic analysis of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol in ginger-containing dietary supplements, spices, teas, and beverages. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856: 41-7.
17. Zick SM, Djuric Z, Ruffin MT, Litzinger AJ, Normolle DP, Alrawi S, et al. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008; 17: 1930-6.
18. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22: 2489-503.
19. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006; 20: 187-210.
20. Eric Y, Kathy A. Interaction of herbal constituents with cytochrome P450 enzymes. Alternative and Complementary Therapies 2007; 13: 239-47.
21. Hao M, Ba Q, Yin J, Li J, Zhao Y, Wang H. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides. Drug Metab Pharmacokinet 2011; 26: 201-5.
22. Trubetskoy OV, Gibson JR, Marks BD. Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 2005; 10: 56-66.
23. Marks BD, Thompson DV, Goossens TA, Trubetskoy OV. High through put screening assays for the assessment of CYP2C9-1, CYP2C9-2, and CYP2C9-3 metabolism using fluorogenic Vivid substrates. J Biomol Screen 2004; 9: 439-49.
24. Marks BD, Smith RW, Braun HA, Goossens TA, Christenson M, Ozers MS, et al. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate. Assay Drug Dev Technol 2002; 1: 73-81.
25. Marks BD, Goossens TA, Braun HA, Ozers MS, Smith RW, Lebakken C, et al. High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates. AAPS PharmSci 2003; 5: E18.
26. Bell L, Bickford S, Nguyen PH, Wang J, He T, Zhang B, et al. Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. J Biomol Screen 2008; 13: 343-53.
27. Zick SM, Ruffin MT, Djuric Z, Normolle D, Brenner DE. Quantitation of 6-, 8- and 10-gingerols and 6-shogaol in human plasma by high-performance liquid chromatography with electrochemical detection. Int J Biomed Sci 2010; 6: 233-40.
28. Nassar AF, Hollenberg PF, Scatina JA. Drug metabolism handbook: concepts and applications. New Jersey: John Wiley & Sons, Inc; 2009.
29. Cohen LH, Remley MJ, Raunig D, Vaz AD. In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003; 31: 1005-15.
30. Magnus IS, Sarah CS, Alvin G, Cristina RA. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
31. Miners JO, Birkett DJ. Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
32. Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals. Toxicol Lett 2006; 162: 16-28.
33. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-94.
34. Hao M, Zhao Y, Chen P, Huang H, Liu H, Jiang H, et al. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One 2008; 3: e2697.
35. Westerink WM, Schoonen WG. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 2007; 21: 1581-91.